EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia

Avichai Shimoni iD, Christophe Peczynski iD, Myriam Labopin, Alexander Kulagin iD, Ellen Meijer, Jan Cornelissen, Goda Choi, Jaime Sanz, Montserrat Rovira, Gwendolyn Van Gorkom, Nicolaus Kröger iD, Yener Koc und 8 weitere

Leukemia · 2025-01 · 39 (1) · 222-228

DOI: 10.1038/s41375-024-02445-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, online erschienen am 31.10.2024. Verfasst von Avichai Shimoni und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Chaim Sheba Medical Center, Tel-Hashomer and Tel-Aviv University, Tel Aviv, Israel. ashimoni@sheba.health.gov.il. Hauptthemen laut MEDLINE: Graft vs Host Disease, Cyclophosphamide, Leukemia, Myeloid, Acute, Graft vs Leukemia Effect. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The association of graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects after allogeneic stem-cell transplantation (SCT) is well-established but was not confirmed in the modern era and following post-transplant cyclophosphamide (PTCy). We assessed GVHD/ GVL association in AML patients following HLA-matched SCT with standard calcineurin-based ( n = 12,653, 57% with additional in-vivo T-cell depletion) or PTCy-based ( n = 508) GVHD prophylaxis. Following standard prophylaxis, acute GVHD grade II-IV and III-IV, chronic GVHD, and extensive chronic GVHD rates were 23.8%, 7.5%, 37.0%, and 16.3%, respectively. Acute GVHD grade II and III-IV were associated with lower relapse [hazard-ratio (HR) 0.85, P = 0.002; HR 0.76, P = 0.003, respectively)], higher non-relapse mortality (NRM) (HR 1.5, P < 0.001; HR 6.21, P < 0.001) and lower overall survival (OS) (HR 1.49, P < 0.001; HR 6.1, P < 0.001). Extensive chronic GVHD predicted lower relapse (HR 0.69, P < 0.001), higher NRM (HR 2.83, P < 0.001), and lower OS (HR 2.74, P < 0.001). Following PTCy, GVHD rates were 22.8%, 6.2%, 35.5%, and 17.7%, respectively. Acute GVHD was not associated with relapse (HR 1.37, P = 0.15) but predicted higher NRM (HR 3.34, P < 0.001) and lower OS (HR 1.92, P = 0.001). Chronic GVHD was not prognostic for these outcomes. In conclusion, GVHD and GVL are strongly associated with contemporary SCT. However, following PTCy, GVHD is not associated with reduced relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseCyclophosphamideLeukemia, Myeloid, AcuteGraft vs Leukemia EffectHematopoietic Stem Cell TransplantationHumansMiddle AgedMaleFemaleAdultAdolescentAgedYoung AdultTransplantation, HomologousImmunosuppressive AgentsHistocompatibility TestingHLA Antigens

Substanzen

CyclophosphamideImmunosuppressive AgentsHLA Antigens

Autor:innen und Institutionen

  • Division of Hematology, Chaim Sheba Medical Center, Tel-Hashomer and Tel-Aviv University, Tel Aviv, Israel. ashimoni@sheba.health.gov.il.
  • Sorbonne University, INSERM UMRs 938, Paris, France.
  • Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia.
  • VU University Medical Center, Department of Hematology, Amsterdam, The Netherlands.
  • Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Hematology, Rotterdam, The Netherlands.
  • University Medical Center Groningen (UMCG), Dept. of Hematology, Groningen, The Netherlands.

ORCID-Profile: Avichai Shimoni, Christophe Peczynski, Alexander Kulagin, Nicolaus Kröger, Amit Patel, Patrizia Chiusolo, Fabio Ciceri

Zitieren

APA

Shimoni, A., Peczynski, C., Labopin, M., Kulagin, A., Meijer, E., Cornelissen, J., Choi, G., Sanz, J., Rovira, M., Van Gorkom, G., Kröger, N., Koc, Y., Vydra, J., Diez-Martin, J. L., Solano, C., Patel, A., Chiusolo, P., Ciceri, F., Nagler, A., & Mohty, M. (2025). Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia. Leukemia, 39(1), 222-228. https://doi.org/10.1038/s41375-024-02445-x

Vancouver

Shimoni A, Peczynski C, Labopin M, Kulagin A, Meijer E, Cornelissen J, et al. Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia. Leukemia. 2025;39(1):222-228. doi:10.1038/s41375-024-02445-x

BibTeX
@article{Shimoni2025,
  author = {Shimoni, Avichai and Peczynski, Christophe and Labopin, Myriam and Kulagin, Alexander and Meijer, Ellen and Cornelissen, Jan and Choi, Goda and Sanz, Jaime and Rovira, Montserrat and Van Gorkom, Gwendolyn and Kröger, Nicolaus and Koc, Yener and Vydra, Jan and Diez-Martin, J L and Solano, Carlos and Patel, Amit and Chiusolo, Patrizia and Ciceri, Fabio and Nagler, Arnon and Mohty, Mohamad},
  title = {Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia},
  journal = {Leukemia},
  year = {2025},
  volume = {39},
  number = {1},
  pages = {222--228},
  doi = {10.1038/s41375-024-02445-x}
}
Kostenlos starten →